(A) JQ1 treatment (1 μM) decreased cell viability of all human neuroblastoma cell lines examined, BE(2)-C, IMR-32, JF, BE(2)-M17, SK-N-SH, and SK-N-DZ (mean ± SEM; *=p < 0.05 vs. CON). Cell viability was measured over a four-day period using CCK-8 assay. (B) JQ1 treatment (1 μM) decreased N-myc protein levels in all neuroblastoma cell lines examined except in MYCN-non-amplified SK-N-SH cells. β-actin was probed for protein loading control.